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Background: In Korea, every vaccine lot is tested by the National Center for Lot Release (NCLR) in accordance with
the national lot release procedures to ensure the safety and efficacy of vaccines. These quality tests examine the
virus content in varicella vaccines via plaque assays (either the agar overlay method [AOM] or plaque staining
method [PSM]), according to the procedures suggested by the Korean Reference Material for the Varicella Vaccine
(KRMVV) or the manufacturer’s standard in-house protocol.
Aim: To standardize the virus content tests, viral titers in the KRMVV were measured using the PSM at four participating
laboratories in a collaborative study. With the aim of developing a standardized method using the KRMVV as a positive
control, we compared the ability of the two test methods, AOM and PSM, to accurately and reproducibly determine
the virus content of two commercial varicella vaccines.
Results: The results showed that the standardized method (PSM) was more suitable for quality control analysis of the
varicella vaccine.
Conclusion: Use of a standardized method (PSM) according to the Korean reference material will improve the reliability
and objectivity of lot release testing.
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Many studies have investigated whether a single infec-
tion with the varicella virus followed by recovery can
confer permanent immunity to all varicella strains [1–3].
In 1974, Takahashi et al. developed a live attenuated
varicella vaccine by isolating the Oka strain from patient
specimens [4]. The vaccines currently used throughout
the world have been developed from several different
strains [5]. In Korea, selective varicella vaccination was
approved and initiated in 1988, and varicella has been
included in the national immunization program since
May 2005. Varicella is designated as a secondary legal* Correspondence: ohojung@korea.kr; pjhak@snu.ac.kr
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creativecommons.org/publicdomain/zero/1.0/communicable disease [6]. Currently, varicella vaccines
originating from the Oka and MAV/06 strains are ap-
proved for use in Korea [5, 7]. The varicella vaccines
used in Korea must contain a viral titer of at least 1000
log10PFU/ dose. Therefore, the virus content is deter-
mined before use. The virus is diluted to within the
range of 10-2 to 10-3, and virus-sensitive cells are then
inoculated with the diluted virus and cultured to form
plaques. Viable cells are stained with a dye, and the
number of plaques formed is counted to calculate the
virus content [8, 9]. Two virus content assays utilized for
national lot release testing (Korean Minimum Require-
ment for Biological Products, Revision 6) use two
different reference materials: Korean reference material
(National Institute of Food & Drug Safety Evaluation,
code no. 08/027) is used for the AOM, and an in-house
standard protocol provided by the manufacturer is used
for the PSM. As such, when using these assays to testicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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an absolute titer or a relative titer. Therefore, to improve
the reliability and objectivity of lot release testing, we
aimed to standardize the testing method and reference
material used for determining virus content.
Materials and methods
Korean reference material for the varicella vaccine
The Korean reference material that is currently being
used for the varicella vaccine was consigned to the
Green Cross Corp. (Korea), first in 2002 (code: 02/006)
and then again in 2009 (code: 08/027), and the MAV/06
strain (from a 33-month-old boy with chickenpox
in1989 in Seoul, Korea) was manufactured for use as a
standard for the AOM [10]. The Korean reference ma-
terial used in this study (code: 08/027), was established
by a collaborative study (assigned titer 4.26 log10PFU/
dose) via AOM [11]. The Korean reference material was
stored at −70 °C, and annual monitoring was conducted
to determine long-term stability.
Sample vaccines
The commercially available products Suduvax (Green
Cross Corp., Korea), produced from a MAV/06 virus
strain, and Varilrix (GlaxoSmithKline, Belgium), pro-
duced from an Oka virus strain, were used as the test
vaccine samples. Each vaccine sample used in the test
was from the same lot that had passed a lot release test
using national lot release procedures.
Cells and methods
We used the same cell line, MRC-5 (pd19, Cat No.
5072101; European Collection of Cell Cultures,
ECACC), for both the AOM and the PSM. MRC-5 cells
were used within 30 population doubling levels (PDLs),
and were maintained at 37 °C and 5 % CO2 in T175
flasks containing minimum essential medium (MEM;
Gibco) supplemented with HEPES (Gibco), 2 mM L-
glutamine (Gibco), antibiotics, and 10 % fetal bovine
serum (FBS; Gibco). Cells were seeded at a density of
0.8–1 × 105 cells/mL for 2 days before infection. In the
AOM, MRC-5 cells were seeded in 6-well plates at a
density of 2.4–3 × 105 cells/well, and were incubated for
2 days at 37 °C and 5 % CO2. A monolayer of cells was
inoculated with dilute virus samples, and was allowed to
be infected for 90 min. The agar overlay medium con-
tained MEM, 10 % FBS, 1 % penicillin (10,000 U/mL)/
streptomycin (10 mg/mL) (Gibco), and 0.8 % (w/v) agar-
ose (Lonza). The agar overlay medium was prepared by
first heating the agar solution at 121 °C for 15 min. The
solution was allowed to cool down to 40 °C prior to the
addition of FBS and antibiotics. Following virus infection
the agar overlay medium (primary overlay) was added to
the wells and allowed to solidify at room temperature.On the fifth day of incubation, a secondary overlay of the
same agar medium was added. Three days after the
addition of the secondary overlay, a third overlay solution
containing 0.33 % (w/v) neutral-red staining solution
(Amresco) was added, and the number of plaques was
then measured as the CPE.
In the liquid medium-based PSM, MRC-5 cells were
seeded in 6-well plates at a density of 3 × 105 cells/well,
and incubated for 2 days at 36 °C and 3 % CO2. A
diluted virus sample was inoculated into a monolayer of
cells and was allowed to be absorbed for 90 min. Cells
were incubated in MEM containing 50 μg/mL neomycin
(Sigma), 7.5 % sodium bicarbonate solution (Gibco), and
2 % FBS (Gibco). After absorption, liquid medium was
added. After 7 days of incubation, the liquid medium
was removed, and cells were stained with 3 mL of Coo-
massie blue stain (Ethanol and Coomassie Brilliant Blue;
Bio-Rad) for 30 min to 3 h. Finally, the number of pla-
ques formed in the plate was counted over a light box.
Collaborative study
The collaborative study was a 2-year project conducted
from 2012 to 2013. In the first year, four laboratories,
including the National Center for Lot Release, Green
Cross Corp. (Korea), SK Chemicals (Korea), and Korea
Vaccine Co. (Korea), participated in the collaborative
study. PSM was used to calculate the assigned titer of
the Korean reference material (code: 08/027), which had
been previously determined using the AOM. In the
second year, we determined the titer of varicella vaccines
that were previously assessed in lot release testing using
both a standardized PSM with the Korean reference
material (code: 08/027) as a positive control, and the
AOM. The results of the two testing methods were then
compared. In 2012, the titer of the Korean reference
material was measured 10 times (in triplicate) using the
PSM at laboratories A, B, and D, and 11 times at labora-
tory C. Analyses were conducted on the results from the
33 tests performed at laboratory C as well as the 30 tests
performed at each of the other three laboratories. In the
second year (2013), with an aim to standardize the virus
content assay used in lot release testing of the commer-
cial varicella vaccine (Suduvax [Green Cross Corp.,
Korea] and Varilrix [GlaxoSmithKline, Belgium]), the
viral titer of each vaccine was tested using a standard-
ized PSM with Korean reference material as a positive
control, and with the AOM. The results of the two test-
ing methods were compared. The same laboratories that
participated in the first year of the project continued to
work as collaborators. In the present collaborative test-
ing, each participating institution used the same method
for AOM. However, in the case of the PSM, protocols at
participating institutions were newly established. Never-
theless, training and SOP transfer from the present
Table 2 Results of the collaborative study using the vaccine
sample (Suduvax (Green Cross Corp., Korea) and Varilrix
(GlaxoSmithKline, Belgium)). The results of the collaborative
study by method were compared to the virus content (titer)
of the vaccine (titer unit: log10PFU/ dose)
Vaccine Laboratorya Method Result
GMTb 95 % C.I.c P-value*
Suduvax A PSMd 3.53 3.49, 3.57 0.8661
AOMe 3.54 3.50, 3.58
B PSMd 4.01 3.98, 4.05 <.0001
AOMe 3.28 3.25, 3.32
C PSMd 3.74 3.67, 3.81 0.4627
AOMe 3.70 3.64, 3.78
D PSMd 3.68 3.66, 3.70 0.3658
AOMe 3.70 3.68, 3.71
Varilrix A PSMd 3.86 3.82, 3.91 0.5064
AOMe 3.88 3.84, 3.93
B PSMd 4.17 4.14, 4.20 <.0001
AOMe 3.46 3.43, 3.49
C PSMd 3.75 3.68, 3.82 <.0001
AOMe 4.02 3.96, 4.10
D PSMd 3.70 3.68, 3.72 <.0001
AOMe 3.76 3.74, 3.78
aLaboratory: one of the participating laboratories, the National Center for Lot
Release, Green Cross Corp. (Korea), SK Chemicals (Korea), and Korea Vaccine
Co. (Korea) (in randomized order)
bGMT, Geometric mean titer
c95 % C.I., 95 % confidence interval
dPSM, Plaque staining method
dAOM, Agar overlay method
*P-value: ANOVA test
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tions performed the experiments independently.
Statistical analysis
The SAS system version 9.2 was used to analyze the all
the data collected.
Results
To confirm the technical proficiency of the test laborator-
ies, z-score analysis was performed. The median titer for
each test organization and the normalized interquartile
range (IQR) were used to calculate a robust z-score to re-
duce the effects of limit values on the entire statistic. In
our collaborative study (2012), the robust z-score was
within ± 1 in all laboratories (A = 0.80 (mean titer = 4.63
log10PFU/ dose), B = −0.96 (mean titer = 4.57 log10PFU/
dose), C = 0.47 (mean titer = 4.36 log10PFU/ dose), and D
= −0.47 (mean titer = 4.43 log10PFU/ dose)); thus, the pro-
ficiencies of the test laboratories were considered to be
sufficient (Table 1). Using the statistical testing methods
described above, significant differences were found be-
tween the results of tests performed at the different
laboratories. However, the results showed a good inter-
laboratory variability (GCV =2.80 %) and the final titer of
the Korean reference material was calculated by combin-
ing the estimated titers from the four laboratories.
The overall titer was estimated by obtaining the geomet-
ric mean titer (GMT) with the non-weighted geometric
mean using the GMT of each laboratory. The final GMT
was 4.50 log10 PFU/ dose, and the geometric coefficient of
variation (GCV) was 2.80 %, indicating that the measure-
ments obtained by the different laboratories were similar.
No difference was observed between the arithmetic mean
and the arithmetic coefficient of variation (ACV).
In the second year (2013), the Korean reference material
and vaccine samples were tested at each laboratory
(Table 2). To confirm the reproducibility of the test results
for the Korean reference material (code: 08/027) and vac-
cine samples, a robust z-score was calculated for the PSMTable 1 Results of the collaborative study using the national standard










aLaboratory: one of the participating laboratories, the National Center for Lot Releas
(Korea) (in randomized order)
bRobust Z score: unlike the normal Z score, a robust Z score is calculated using the
standard deviation. When the robust z-score was < |2|, the proficiency of the test la
cMultiple Comparison: p-value adjusted by Bonferroni method
*P-value: ANOVA testand AOM at each concentration. The robust z-score was
less than |2| for the two virus content tests and laborator-
ies, indicating a satisfactory proficiency data not shown).
In order to test the difference of potencies between the
test agencies, One-way ANOVA analysis was performed.
Potency of live varicella virus vaccine was calculated based(National Institute of Food & Drug Safety Evaluation, code no. 08/
he 4 participating laboratories (A, B, C, and D) were compared
parisonc
A vs. C A vs. D B vs. C B vs. D C vs. D
<.0001 <.0001 <.0001 <.0001 0.0063
e, Green Cross Corp. (Korea), SK Chemicals (Korea), and Korea Vaccine Co.
median and absolute deviation from median instead of the mean and
boratories was considered satisfactory
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repeat was regarded as one independent experiment, and
significant differences between test agencies were found
(p < .0001). When multiple comparisons were performed
by application of the Bonferroni method as a post-hoc
comparison, every combination of institutions except A la-
boratory and B laboratory showed significant differences
between institutions. However, geometric coefficients of
variation (GCV) between test agencies were 1.09 % for A
laboratory, 3.45 % for B laboratory, 0.98 % for C labora-
tory, and 0.37 % for D laboratory. This indicates that varia-
tions between test agencies were less than 5 %, confirming
high reproducibility of the assay.
Collaborative studies on the Korean reference material
(code: 08/027) for the varicella vaccine began in 2009
[11]. Three laboratories participated every year, and an-
other laboratory was added after 2012, bringing the total
number of participating laboratories to four. To investi-
gate the differences in test results between two methods,
and to compare titers determined at the time of first
manufacture and at the fifth year of manufacturing, we
compared test method-based, year-based, and overall
data, as described below. Table 3 shows a comparison of
the virus content test methods for each year, which falls
within an acceptance range of ± 0.5 log10PFU/ dose for
each assigned titer. Comparison of the data collected in
2009 and 2012 showed that the difference between the
test methods was 0.24 log10PFU/ dose (95 % confidence
interval [CI], 0.18–0.30), which was within the accept-
ance range (−0.5–0.5 log10PFU/ dose), suggesting that
the results of the two test methods were not significantly
different. Analysis of the data collected in 2013 showed
that the difference between the test methods was 0.19
log10PFU/ dose and that the 95 % CI (0.07–0.30) was
within the acceptance range, further confirming that the
results of the two methods were not significantlyTable 3 Results of the collaborative study using the national
standard (National Institute of Food & Drug Safety Evaluation,
code no. 08/027) by year and method. The results of the virus
content testing were compared to the test results of each
collaborative study during 2009 ~ 2013 (titer unit: log10PFU/ dose)
Method Experiment Result
Nd Meane ± SDf 95 % CIg
PSMa CSVc 2012 41 4.50 ± 0.14 −0.01, 0.09
CSVc 2013 40 4.46 ± 0.14
AOMb CSVc 2009 25 4.26 ± 0.09 −0.15, 0.12
CSVc 2013 40 4.27 ± 0.34
aPSM, Plaque staining method
bAOM, Agar overlay method
cCVA, Collaborative study for Varicella national standard material
dN, Number of tests
eMean, Geometric mean titer
fSD, Standard deviation
gCI, confidence intervaldifferent. The differences between the data obtained in
different implementation years were 0.04 log10PFU/
dose (95 % CI, −0.01–0.09) and −0.01 log10PFU/ dose
(95 % CI, −0.15–0.12) for the PSM and AOM, respect-
ively. These values were within the acceptance range (
−0.5–0.5 log10PFU/ dose), indicating that the results
obtained in different implementation years did not dif-
fer significantly (Table 3). For the overall data, the 95 %
CI was within the acceptance range (0.22 log10PFU/
dose; 95 % CI, 0.17–0.27), confirming that the results
obtained using the two methods did not differ signifi-
cantly (Table 4).
Discussion
The Korean reference material was established by a
previous collaborative study, which included the manu-
facturers [11]. However, in products that use the Oka
strain, the virus content is usually measured by the
PSM. For national lot release testing, quality control of
all domestic products is performed using the AOM and
PSM before human use. As such, we conducted this
study to analyze varicella vaccines developed using
different strains of virus with the aim of developing an
accurate and reproducible test method, confirming its
feasibility, and standardizing the method and reference
material used for lot release testing.
The use of the PSM could shorten the test period from
11 days, which is required for the current AOM, to 9
days. Moreover, the use of the PSM could also reduce
the workload of laboratory technicians secondary and
tertiary overlays are omitted, and cell fixation and stain-
ing can be performed simultaneously. In addition, the
plaques formed using the PSM staining method are
more vivid and clear than those formed using the AOM,
yielding more objective and accurate results. In this
study, we showed that virus content testing performed
using standardized methods and the same reference ma-
terial will increase the reliability of the results, and lead
to more consistent quality control of vaccine products.Table 4 Analysis of the overall data from the collaborative
study. The results of the collaborative study by method were
compared to the virus content (titer) of the national standard
(National Institute of Food & Drug Safety Evaluation, code no.
08/027) (titer unit: log10PFU/dose)
Method Result
Nc Meand ± SDe 95 % CIf
PSMa 81 4.50 ± 0.14 0.17, 0.27
AOMb 65 4.27 ± 0.26
aPSM, Plaque staining method
bAOM, Agar overlay method
cN, Number of tests
dMean, Geometric mean titer
eSD, Standard deviation
fCI, Confidence interval
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Varicella infections typically occur in children, mainly due
to primary infection by the varicella virus. In contrast,
shingles occurs in elderly or immune-compromised indi-
viduals due to activation of the latent virus [12]. Currently,
domestic pharmaceutical companies and foreign compan-
ies, including GlaxoSmithKline (Belgium) and Merck
(USA), are actively performing studies to develop varicella
and shingles vaccines [13, 14]. The data presented in our
current study will help to provide more accurate and
reliable quality control measures for the current vaccine
market. In addition, these results may lead to advance-
ment in studies on various novel products, including
recombinant varicella vaccines.
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